COGNY yields 4.85% · MRK yields 2.76%● Live data
📍 MRK pulled ahead of the other in Year 1
Combined, COGNY + MRK cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of COGNY + MRK for your $10,000?
Cogna Educação S.A. operates as a private educational organization in Brazil and internationally. The company operates through three segments: In-Class Higher Education, Distance Learning Higher Education, and Basic Education. It offers in-class and distance-learning higher education, and undergraduate and graduate courses; publishes, sells, and distributes textbooks, support materials, and workbooks with educational, literary, and informative content and teaching systems; and educational solutions for professional and higher education, and other supplementary activities, such as developing education technology with management and other education services. The company also provides K-12 education, pre-college preparatory, language courses for children and teenagers; management of child, primary, and secondary education activities; technical and preparatory courses for civil service examinations and Brazilian Bar Association; advises on and/or facilitates direct and indirect student loans; and develops software for adaptive teaching and academic management optimization. Its services include primary, secondary, and postsecondary education services with on-campus undergraduate and graduate programs, and distance learning, as well as graduate programs; preparatory courses under the brand LFG; and unregulated programs. The company operates 176 college education units in 24 Brazilian states and 132 Brazilian cities; and 1,510 distance-learning graduation centers in various Brazilian states and in the Federal District, as well as operates 54 own K-12 education schools, 125 Red Balloon units, and approximately 5,600 associated schools in Brazil. Cogna Educação S.A. was founded in 1998 and is headquartered in Belo Horizonte, Brazil.
Full COGNY Calculator →Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Full MRK Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.